Market Overview

UPDATE: Oppenheimer Raises PT on Celldex Therapeutics on Key Clinical Milestones, Associated Trials Anticipated In 2H13

Share:
Related CLDX
Celldex Offers Safety Profile, Immuno Response Data from Phase 1/2 Study of Varlilumab, Nivolumab at AACR Meeting
Benzinga's Top Downgrades

In a report published on Friday, Oppenheimer analyst Boris Peaker raised the price target on Celldex Therapeutics (NASDAQ: CLDX) from $14 to $16 and reiterated a rating of Outperform on the company.

In the report, Oppenheimer stated, "We believe that investors will be focused on the Rindo studies in brain cancer as well as initial data for CDX-1135 and CDX-1127. Additionally, we performed further due diligence on CDX-1135 and we are adding this compound to our valuation. This is the basis for our price target increase of $2/share (from $14 to $16)."

Celldex Therapeutics closed on Thursday at $14.29.

Latest Ratings for CLDX

DateFirmActionFromTo
Mar 2016JefferiesDowngradesBuyHold
Mar 2016Cowen & CompanyMaintainsOutperform
Mar 2016H.C. WainwrightMaintainsBuy

View More Analyst Ratings for CLDX
View the Latest Analyst Ratings

Posted-In: Boris Peaker OppenheimerAnalyst Color Price Target Analyst Ratings

 

Related Articles (CLDX)

View Comments and Join the Discussion!